Citadel Advisors’s Grace Therapeutics GRCE Stock Holding History

Citadel Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$119K	Buy	+52,500	New	+$145K	﹤0.01%	12540

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Citadel Advisors's GRCE Position: Q2 2026 in Review

Citadel Advisors increased its Grace Therapeutics (GRCE) stake by 254% in Q2 2026, buying an estimated $694K and bringing the position to 349,740 shares worth $794K. The position accounts for ﹤0.01% of the portfolio, ranked #8777.

Citadel Advisors first reported a position in GRCE in Q1 2014 and has held it in 25 quarters since. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Citadel Advisors held 349,740 shares of Grace Therapeutics worth $794K as of Q2 2026.
Citadel Advisors bought 250,998 Grace Therapeutics shares in Q2 2026, an estimated $694K.
Grace Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8777 holding.
Citadel Advisors first reported a position in Grace Therapeutics in Q1 2014 and has held it in 25 quarters since.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.